Home    Back

Mis416    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica2

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02228213
(ClinicalTrials.gov)		October 201421/8/2014Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple SclerosisA Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisBiological: MIS416;Drug: SalineInnate ImmunotherapeuticsINC ResearchCompleted18 Years70 YearsAll93Phase 2Australia;New Zealand
2NCT01191996
(ClinicalTrials.gov)		August 201030/8/2010Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple SclerosisA Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis;Primary Progressive Multiple SclerosisBiological: MIS416Innate ImmunotherapeuticsPrimorus Clinical Trials;National Multiple Sclerosis SocietyCompleted18 YearsN/ABoth34Phase 1;Phase 2New Zealand